Anteris Technologies Global AVR
NASDAQ AVR
$7.77 +0.18 (+2.37%)
At close: Sep 30, 2026 · 4:00 PM EDT

Anteris Technologies Global (AVR) Retained Earnings (2024 - 2026)

Updated

Anteris Technologies Global (AVR) recorded Retained Earnings of -$422.65 million in Q2 2026, compared with -$319.09 million a year earlier.

Analysis

Anteris Technologies Global (AVR) Retained Earnings (2024 - 2026) Analysis & Trends

At the end of FY2025, Anteris Technologies Global reported Retained Earnings of -$370.53 million.

  • Across earlier years, Retained Earnings came in at -$276.39 million in FY2024.
  • Per Business Quant, the preceding three quarters came in at -$393.56 million (Q1 2026), -$370.53 million (Q4 2025) and -$341.33 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Thermo Fisher Scientific 249.71 Bn 228.86 Bn 4.88 Bn 62.19 Bn
2 Abbott Laboratories 171.00 Bn 142.08 Bn 7.27 Bn 49.79 Bn
3 Danaher 155.79 Bn 139.61 Bn 3.61 Bn 48.23 Bn
4 Intuitive Surgical 143.91 Bn 123.46 Bn 1.96 Bn 6.84 Bn
5 Medtronic 110.42 Bn 76.29 Bn 6.34 Bn 33.19 Bn
6 Stryker 105.71 Bn 91.82 Bn 4.50 Bn 21.82 Bn
7 Boston Scientific 63.26 Bn 58.27 Bn 3.85 Bn 7.82 Bn
8 Edwards Lifesciences 49.80 Bn 33.91 Bn 1.35 Bn 14.86 Bn
9 Becton Dickinson 48.78 Bn 45.93 Bn 2.32 Bn 17.51 Bn
10 Anteris Technologies Global 756.88 Mn 757.17 Mn 776,000.00 -422.65 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -422.65 Mn
Mar 31, 2026 -393.56 Mn
Dec 31, 2025 -370.53 Mn
Sep 30, 2025 -341.33 Mn
Jun 30, 2025 -319.09 Mn
Mar 31, 2025 -298.25 Mn
Dec 31, 2024 -276.39 Mn
API Access

Anteris Technologies Global Retained Earnings API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=retained-earnings&ticker=AVR&period=max&api_key=YOUR_API_KEY